# A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis

> **NCT01214733** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 30 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01214733
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214733, "A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01214733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*